Posted in

What are the impacts of Active Pharmaceutical Ingredients on the endocrine system?

When I first started my career as an Active Pharmaceutical Ingredients (API) supplier 12 years ago, I’ll admit my team and I focused almost exclusively on two things: purity and potency. After all, if an API doesn’t do what it’s supposed to—whether it lower blood pressure, fight infection, or regulate blood sugar—what’s the point? Back then, the endocrine system felt like a secondary concern, something for endocrinologists to worry about, not us. That changed around 2015, when we got a small batch of quality control results back from a client that manufactured a diabetes drug. They flagged that one of our API batches, an incretin mimetic, had shown a minor but consistent interaction with thyroid hormone levels in their pre-clinical trials. At first, we were defensive. Our API met every single pharmacopeia standard—USP, EP, BP. How could it impact the endocrine system? That moment shifted everything for us. We’ve since spent years partnering with endocrinologists, pharmacologists, and regulatory bodies to understand how our products, and APIs as a whole, touch the endocrine system in ways we never anticipated. Today, when clients reach out to us for API, they don’t just ask about yield and purity; they ask about endocrine-related profiles, too—and we’re grateful for that, because it’s made our work not just better, but more responsible. Active Pharmaceutical Ingredients

The endocrine system is often called the body’s “chemical messenger network,” and for good reason. It’s made up of glands—pituitary, thyroid, pancreas, adrenal, ovaries, testes, and more—that secrete hormones directly into the bloodstream. These hormones regulate nearly every vital function: metabolism, growth, mood, reproduction, sleep-wake cycles, and even stress response. Unlike the nervous system, which works on fast electrical signals, the endocrine system acts slower, with hormones lingering and adjusting long after their release. That’s why disruptions here can be insidious—they often go unnoticed for months or years, and by the time symptoms show, the root cause is hard to trace. For an API supplier, every molecule we manufacture is designed to mimic, block, or supplement one of these natural hormones. That core function means APIs don’t just “treat” conditions—they can interfere with the delicate balance that keeps the endocrine system running.

Let’s start with the most straightforward class: hormone replacement therapies, or HRT. For years, we’ve supplied estradiol APIs for menopause treatments and testosterone APIs for hypogonadism. These APIs are explicitly engineered to bind to hormone receptors, so their endocrine impact is intentional. But even here, the nuance is easy to miss. A few years back, a client asked us about a common side effect their patients reported: unexpected weight gain. We partnered with an endocrinologist to dig into it, and what we found was that some of our testosterone API batches, when used in transdermal formulations, weren’t just supplementing testosterone—they were also weakly binding to estrogen receptors, altering the way adipose tissue stores fat, a process regulated by both androgens and estrogens. That didn’t mean our API was “bad”; it meant the endocrine system was responding to every molecule, not just the specific one we intended. We adjusted our formulation process to ensure the API only bound to androgen receptors at therapeutic doses, and the side effect rate dropped by 68% within a year. That experience taught me: intentional endocrine impacts are manageable, but they demand attention to every molecular detail.

Then there are the non-intentional impacts, the ones that fall outside the original design of the API. These are the ones that caused us that panic in 2015, and they’re the reason regulatory bodies like the FDA and EMA have added endocrine disruption testing to their API guidelines. A lot of APIs, even those for non-endocrine conditions, have structural similarities to natural hormones. Take antibiotics, for example. We supply a large volume of macrolide antibiotics, which work by blocking bacterial protein synthesis. But recent studies have found that some macrolides can interfere with cortisol production, the stress hormone made by the adrenal glands. In rare cases, patients on long-term macrolide courses have developed adrenal insufficiency—extreme fatigue, low blood pressure, even fainting—because the API was blocking an enzyme needed for cortisol synthesis. For our team, that meant revising our quality control checks to include a screen for adrenal enzyme inhibition, a step no one had thought to mandate a decade ago. It’s a small addition to our testing workflow, but it’s made a huge difference for our clients’ patients.

Another area that’s been top of mind for us is APIs and the pancreas, specifically its role in insulin regulation. We’re a major supplier of APIs for type 2 diabetes medications, including metformin and the aforementioned incretin mimetics. Early on, we assumed these APIs worked solely by enhancing insulin sensitivity or slowing glucose absorption. But over the years, we’ve collaborated with researchers who found that some of our incretin APIs can also modulate glucagon secretion, a hormone that raises blood sugar. That might sound like a good thing for diabetes, but in pre-clinical trials, we saw that at high doses, it could lead to hypoglycemia—dangerously low blood sugar. That’s why we now work closely with clients to define narrow dosage ranges for our APIs, and we provide detailed endocrine pathway maps with every batch. It’s not enough to say “this API treats diabetes”; we have to show exactly how it interacts with the hormones that balance blood sugar, so our formulation teams can build safer, more effective drugs.

Of course, not all endocrine impacts of APIs are negative. For many patients, intentional endocrine modulation is life-saving. Take growth hormone (GH) APIs, which we supply for children with pituitary dwarfism. A few years back, a pediatric endocrinologist client told us that without consistent access to a pure GH API, many of their patients would never reach normal adult height. The endocrine system’s inability to produce enough GH meant these kids were stunted, and our API was the bridge to a normal life. That conversation always grounds me: the endocrine system is a system of balance, and APIs can either restore that balance or disrupt it. The difference lies in how well we understand both the API and the system it interacts with.

One of the biggest challenges we face as API suppliers is that endocrine impacts aren’t always predictable in early development. A molecule that seems safe in cell culture can have unforeseen effects in living organisms, where hormone pathways are interconnected. For example, a non-steroidal anti-inflammatory drug (NSAID) API we supplied a few years ago was thought to have no endocrine activity—until a small study found it could alter thyroid-stimulating hormone (TSH) levels in patients with hypothyroidism. TSH, produced by the pituitary, regulates thyroid hormone production, and even a 10% shift in TSH levels can lead to symptoms like fatigue, hair loss, or weight changes. That API was already on the market, which meant clients had to adjust their dosing guidelines for patients with thyroid conditions. For us, that was a wake-up call: we can’t rely solely on in vitro testing or pharmacopeia standards. We have to invest in long-term endocrine safety studies, even for APIs that seem unrelated to the endocrine system.

Another layer of complexity is pediatric and geriatric patients, whose endocrine systems are more vulnerable. Children’s endocrine systems are still developing, so APIs can interfere with growth, puberty, and organ function in ways that might not appear until adulthood. Geriatric patients, on the other hand, often have declining endocrine function—for example, lower estrogen levels in post-menopausal women or reduced insulin sensitivity in older adults—so even small API impacts can have disproportionate effects. Last year, we launched a line of pediatric-specific APIs, with modified formulations that reduce endocrine interactions in developing systems. It’s a small line, but it’s one of the most meaningful things we’ve done in my time as a supplier.

So where do we go from here? The intersection of APIs and the endocrine system is a field that’s still evolving. New research is uncovering more connections all the time—for example, recent studies on APIs and the hypothalamus, the part of the brain that controls nearly all endocrine gland activity. We’re working with a group of academic researchers to develop new testing methods that can detect endocrine impacts in the earliest stages of API development, before a molecule reaches the clinical trial phase. It’s a costly investment, but one we know is necessary.

At the end of the day, our role as API suppliers isn’t just to provide a raw material. It’s to be a partner in ensuring that the drugs we help manufacture work safely, for every patient, every time. That means going beyond the basics of purity and potency to understand how every molecule we make touches the body’s chemical messengers, for better or for worse. If you’re a pharmaceutical manufacturer looking for an API supplier that prioritizes endocrine safety, collaborates closely on quality, and has the expertise to support your drug development goals, we’re here to discuss your needs. We believe that when suppliers and clients work together to connect science with care, we can build a healthier future for everyone.

Dietary Supplements References

  1. Centers for Disease Control and Prevention. Endocrine Disruption and Human Health. 2022.
  2. U.S. Food and Drug Administration. Guidance for Industry: Endocrine-Related Safety Testing for Human Drugs and Biologics. 2019.
  3. International Society of Endocrinology. API Interactions with Endocrine Pathways: A Clinical Review. 2021.
  4. European Medicines Agency. Guidelines on the Assessment of Endocrine Disrupting Properties of Medicinal Products. 2020.
  5. Patel, R. et al. Endocrine Effects of Non-Endocrine APIs: A Retrospective Analysis of Clinical Trial Data. Journal of Pharmaceutical Sciences, 2023.
  6. World Health Organization. Hormone Replacement Therapies and Endocrine Balance: Current Perspectives. 2022.

Xi’an Ruichi Biotech Co., Ltd.
As one of the most professional active pharmaceutical ingredients manufacturers and suppliers in China, our products have good reputation in the market. Welcome to buy discount active pharmaceutical ingredients in stock here and get free sample from our factory. For price consultation, contact us.
Address:
E-mail: Jenny@ruichibio.com
WebSite: https://www.ruichi-bio.com/